Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment in its Phase III osteoarthritis (OA) trial using iPPS, which allows the company to post interim efficacy data around August.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with PAR and is intended for informational purposes only.
And on top of that, the company has now inked a partnership with the University of London’s City St. George’s to engage in a research-minded collaborative effort investigating bone marrow lesions in patients with OA.
For those out of the loop, such lesions tend to occur in patients with OA.
In between the lines, it looks like the company’s injectable pentosan polysulfate – sourced ultimately from beech trees – will assess the impact of iPPS on bone and cartilage, as well as ‘synovial inflammation.’
(In other words: the swelling of membranes lining joints, a side effect of arthritis itself and perhaps part of the overall condition’s suite of impacts on the human body.)
“Bone marrow lesions represent one of the most significant and painful aspects of osteoarthritis, yet we still have much to learn about how best to target them,” CGUL Professor of Rheumatology Nidhi Sofat said.
“This collaboration has the potential to deepen our understanding of how pentosan polysulfate works in osteoarthritis.”
For his part, Paradigm Founder Paul Rennie says the partnership is a source for delight.
“Paradigm is delighted to be working with one of the most advanced rheumatology research centres globally on this important program,” Rennie said.
“By combining advanced imaging with molecular profiling, this study has the potential to generate valuable translational data supporting PPS’ activity across multiple joint tissues.”
PAR last traded at 26cps.
Join the discussion: See what HotCopper users are saying about PAR and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.